Vimarsana
Biggest News Aggregation in the World

Page 7 - Initial Results News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Initial Results. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Initial Results Today - Breaking & Trending Today

POINT Biopharma Announces Poster Presentation at ESMO - Vimarsana News

POINT Biopharma Announces Poster Presentation at ESMO

Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. ...

POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial - Vimarsana News

POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

05.09.2022 - Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) - POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, ... Seite 1

Investegate |Power Metal Announcements | Power Metal: Tati Gold Project Botswana - Vimarsana News

Investegate |Power Metal Announcements | Power Metal: Tati Gold Project Botswana

Investegate announcements from Power Metal, Tati Gold Project Botswana - Exploration Update

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial - Vimarsana News

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

18.08.2022 - In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at https://hub.pointbiopharma.com/controlarm INDIANAPOLIS, Aug. 18, 2022 (GLOBE ... Seite 1

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial - Vimarsana News

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com